ETTX Entasis Therapeutics Holdings Inc.

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing ETX2514SUL, a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, an oral antibiotic monotherapy that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and various antibiotics for gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Drugs for Neglected Diseases initiative. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts.

As of 06/30/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/26/2018
Outstanding shares:  47,851,779
Average volume:  147,593
Market cap:   $104,795,396
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   6.29
PS ratio:   0.00
Return on equity:   -521.56%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy